tetano
Editor, Senior Moderator
Biomaterials. 2019 Jun 26;217:119308. doi: 10.1016/j.biomaterials.2019.119308. [Epub ahead of print]
[h=1]Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity.[/h] Sanchez-Guzman D[SUP]1[/SUP], Le Guen P[SUP]2[/SUP], Villeret B[SUP]1[/SUP], Sola N[SUP]1[/SUP], Le Borgne R[SUP]3[/SUP], Guyard A[SUP]4[/SUP], Kemmel A[SUP]1[/SUP], Crestani B[SUP]2[/SUP], Sallenave JM[SUP]1[/SUP], Garcia-Verdugo I[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Most of current influenza virus vaccines fail to develop a strong immunity at lung mucosae (site of viral entry) due to sub-optimal vaccination protocols (e.g. inactivated virus administered by parenteral injections). Mucosal immunity could be improved by using locally-delivered vaccines containing appropriate adjuvants. Here we show, in a mouse model, that inclusion of silver nanoparticles (AgNPs) in virus-inactivated flu vaccine resulted in reduction of viral loads and prevention of excessive lung inflammation following influenza infection. Concomitantly, AgNPs enhanced specific IgA secreting plasma cells and antibodies titers, a hallmark of successful mucosal immunity. Moreover, vaccination in the presence of AgNPs but not with gold nanoparticles, protected mice from lethal flu. Compared with other commercial adjuvants (squalene/oil-based emulsion) or silver salts, AgNPs stimulated stronger antigen specific IgA production with lower toxicity by promoting bronchus-associated lymphoid tissue (BALT) neogenesis, and acted as a bona fide mucosal adjuvant.
Copyright ? 2019 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Adjuvant; Immunity; Influenza virus; Lung vaccination; Silver nanoparticles; Vaccine
PMID: 31279103 DOI: 10.1016/j.biomaterials.2019.119308
[h=1]Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity.[/h] Sanchez-Guzman D[SUP]1[/SUP], Le Guen P[SUP]2[/SUP], Villeret B[SUP]1[/SUP], Sola N[SUP]1[/SUP], Le Borgne R[SUP]3[/SUP], Guyard A[SUP]4[/SUP], Kemmel A[SUP]1[/SUP], Crestani B[SUP]2[/SUP], Sallenave JM[SUP]1[/SUP], Garcia-Verdugo I[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Most of current influenza virus vaccines fail to develop a strong immunity at lung mucosae (site of viral entry) due to sub-optimal vaccination protocols (e.g. inactivated virus administered by parenteral injections). Mucosal immunity could be improved by using locally-delivered vaccines containing appropriate adjuvants. Here we show, in a mouse model, that inclusion of silver nanoparticles (AgNPs) in virus-inactivated flu vaccine resulted in reduction of viral loads and prevention of excessive lung inflammation following influenza infection. Concomitantly, AgNPs enhanced specific IgA secreting plasma cells and antibodies titers, a hallmark of successful mucosal immunity. Moreover, vaccination in the presence of AgNPs but not with gold nanoparticles, protected mice from lethal flu. Compared with other commercial adjuvants (squalene/oil-based emulsion) or silver salts, AgNPs stimulated stronger antigen specific IgA production with lower toxicity by promoting bronchus-associated lymphoid tissue (BALT) neogenesis, and acted as a bona fide mucosal adjuvant.
Copyright ? 2019 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Adjuvant; Immunity; Influenza virus; Lung vaccination; Silver nanoparticles; Vaccine
PMID: 31279103 DOI: 10.1016/j.biomaterials.2019.119308